{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:35:38Z","timestamp":1792236938146,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001352","name":"National University of Singapore","doi-asserted-by":"publisher","award":["C-148-000-003-001"],"award-info":[{"award-number":["C-148-000-003-001"]}],"id":[{"id":"10.13039\/501100001352","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001459","name":"Ministry of Education - Singapore","doi-asserted-by":"publisher","award":["R-148-000-193-112"],"award-info":[{"award-number":["R-148-000-193-112"]}],"id":[{"id":"10.13039\/501100001459","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.bcp.2016.03.005","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T12:27:05Z","timestamp":1457612825000},"page":"67-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites"],"prefix":"10.1016","volume":"107","author":[{"given":"Aneesh","family":"Karkhanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Yuan","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopalakrishnan","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Kwan","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Li Lin","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pipin","family":"Kojodjojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6107-9072","authenticated-orcid":false,"given":"Eric Chun Yong","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2016.03.005_b0005","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2016.03.005_b0010","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/europace\/eur194","article-title":"The cost of illness of atrial fibrillation: a systematic review of the recent literature","volume":"13","author":"Wolowacz","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.bcp.2016.03.005_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pcad.2005.06.001","article-title":"Epidemiological profile of atrial fibrillation: a contemporary perspective","volume":"48","author":"Tsang","year":"2005","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.bcp.2016.03.005_b0020","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1476-5381.1970.tb09891.x","article-title":"The effect of amiodarone, a new anti-anginal drug, on cardiac muscle","volume":"39","author":"Singh","year":"1970","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2016.03.005_b0025","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1592\/phco.30.9.904","article-title":"Dronedarone: a new antiarrhythmic agent","volume":"30","author":"Oyetayo","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bcp.2016.03.005_b0030","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/CIRCULATIONAHA.109.858027","article-title":"Dronedarone","volume":"120","author":"Patel","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2016.03.005_b0035","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMoa0800456","article-title":"Increased mortality after dronedarone therapy for severe heart failure","volume":"358","author":"K\u00f8ber","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2016.03.005_b0040","author":"USFDA"},{"key":"10.1016\/j.bcp.2016.03.005_b0045","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/j.1875-9114.2012.01118.x","article-title":"Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reporting","volume":"32","author":"Kao","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bcp.2016.03.005_b0050","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4997\/jrcpe.2015.308","article-title":"Organising pneumonia due to dronedarone","volume":"45","author":"Thornton","year":"2015","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"10.1016\/j.bcp.2016.03.005_b0055","author":"USFDA"},{"key":"10.1016\/j.bcp.2016.03.005_b0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/mol.115.100891","article-title":"Inactivation of human cytochrome P450 3A4 and 3A5 by dronedarone and N-desbutyl dronedarone","volume":"89","author":"Hong","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2016.03.005_b0065","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4137\/CMC.S8445","article-title":"Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation","volume":"7","author":"Heijman","year":"2013","journal-title":"Clin. Med. Insights Cardiol."},{"key":"10.1016\/j.bcp.2016.03.005_b0070","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0163-7258(95)02013-6","article-title":"The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity","volume":"68","author":"Park","year":"1995","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2016.03.005_b0075","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1124\/dmd.106.012823","article-title":"Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues","volume":"35","author":"Delozier","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.03.005_b0080","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1124\/dmd.109.030270","article-title":"Identification of novel substrates for human cytochrome P450 2J2","volume":"38","author":"Lee","year":"2010","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.03.005_b0085","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pharmthera.2005.05.011","article-title":"Cytochrome P450 enzymes: central players in cardiovascular health and disease","volume":"112","author":"Elbekai","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2016.03.005_b0090","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00021.2001","article-title":"P-450 metabolites of arachidonic acid in the control of cardiovascular function","volume":"82","author":"Roman","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bcp.2016.03.005_b0095","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073490","article-title":"CYP2J2 overexpression protects against arrhythmia susceptibility in cardiac hypertrophy","volume":"8","author":"Westphal","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2016.03.005_b0100","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1210\/en.2012-2166","article-title":"Cardiac-specific overexpression of CYP2J2 attenuates diabetic cardiomyopathy in male streptozotocin-induced diabetic mice","volume":"154","author":"Ma","year":"2013","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2016.03.005_b0105","doi-asserted-by":"crossref","first-page":"H37","DOI":"10.1152\/ajpheart.00983.2008","article-title":"Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity","volume":"297","author":"Zhang","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.bcp.2016.03.005_b0110","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1124\/dmd.111.043505","article-title":"Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity","volume":"40","author":"Lee","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.03.005_b0115","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1016\/j.jchromb.2011.09.004","article-title":"Simultaneous determination of dronedarone and its active metabolite debutyldronedarone in human plasma by liquid chromatography\u2013tandem mass spectrometry: application to a pharmacokinetic study","volume":"879","author":"Xie","year":"2011","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.bcp.2016.03.005_b0120","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0090-9556(24)15358-5","article-title":"In vitro\u2013in vivo scaling of CYP kinetic data not consistent with the classical Michaelis\u2013Menten model","volume":"28","author":"Houston","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.03.005_b0125","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1124\/dmd.30.4.355","article-title":"Atypical kinetic profiles in drug metabolism reactions","volume":"30","author":"Hutzler","year":"2002","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.03.005_b0130","first-page":"550","article-title":"The rational selection of drug interaction studies: implications of recent advances in drug metabolism","volume":"30","author":"Tucker","year":"1992","journal-title":"Int. J. Clin. Pharmacol. Ther. Toxicol."},{"key":"10.1016\/j.bcp.2016.03.005_b0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bcp.2014.06.020","article-title":"Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo","volume":"91","author":"Kaspera","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2016.03.005_b0140","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0076-6879(95)49038-8","article-title":"Mechanism-based enzyme inactivators","volume":"249","author":"Silverman","year":"1995","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bcp.2016.03.005_b0150","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/jpet.300.1.298","article-title":"Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes","volume":"300","author":"Hashizume","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2016.03.005_b0155","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1128\/AAC.00843-13","article-title":"CYP2J2 and CYP2C19 are the major enzymes responsible for metabolism of albendazole and fenbendazole in human liver microsomes and recombinant P450 assay systems","volume":"57","author":"Wu","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2016.03.005_b0160","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1124\/dmd.106.010488","article-title":"Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A","volume":"34","author":"Liu","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.03.005_b0165","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1124\/dmd.112.048264","article-title":"Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors","volume":"41","author":"Ren","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.03.005_b0170","author":"USFDA"},{"key":"10.1016\/j.bcp.2016.03.005_b0175","author":"USFDA"},{"key":"10.1016\/j.bcp.2016.03.005_b0180","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(87)80320-0","article-title":"Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity","volume":"9","author":"Greenberg","year":"1987","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2016.03.005_b0185","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0735-1097(84)80367-8","article-title":"Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects","volume":"3","author":"Zipes","year":"1984","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.bcp.2016.03.005_b0190","doi-asserted-by":"crossref","first-page":"45F","DOI":"10.1016\/0002-9149(93)90962-C","article-title":"Pharmacokinetics of amiodarone: implications for drug therapy","volume":"72","author":"Roden","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.bcp.2016.03.005_b0195","doi-asserted-by":"crossref","first-page":"407","DOI":"10.2174\/138920007780866807","article-title":"Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure\u2013activity relationships and relationship to clinical drug\u2013drug interactions and idiosyncratic adverse drug reactions","volume":"8","author":"Kalgutkar","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bcp.2016.03.005_b0200","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","article-title":"The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America","volume":"37","author":"Grimm","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bcp.2016.03.005_b0205","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/0076-6879(91)06126-N","article-title":"Cytochrome P450 metabolic intermediate complexes from macrolide antibiotics and related compounds","volume":"206","author":"Franklin","year":"1991","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bcp.2016.03.005_b0210","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/0006-2952(79)90409-X","article-title":"Cytochrome P-455 complex formation in the metabolism of phenylalkylamines-IV. Spectral evidences for metabolic conversion of methamphetamine to N-hydroxyamphetamine","volume":"28","author":"Lindeke","year":"1979","journal-title":"Biochem. Pharmacol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216001581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295216001581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T14:42:58Z","timestamp":1748788978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295216001581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":41,"alternative-id":["S0006295216001581"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2016.03.005","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple modes of inhibition of human cytochrome P450 2J2 by dronedarone, amiodarone and their active metabolites","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2016.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}